CA
AUTL

Claro Advisors’s Autolus Therapeutics AUTL Stock Holding History

Claro Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.3K Buy
+12,500
New +$19K ﹤0.01% 506

Other funds holding AUTL

MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Claro Advisors's AUTL Position: Q1 2026 in Review

Claro Advisors opened a new position in Autolus Therapeutics (AUTL) in Q1 2026: 12,500 shares worth $17.3K. The stake represents ﹤0.01% of the portfolio and ranks #506 among its holdings.

84 funds tracked by Wall St. Rank hold AUTL as of Q1 2026.

  • Claro Advisors held 12,500 shares of Autolus Therapeutics worth $17.3K as of Q1 2026.
  • Autolus Therapeutics was a new Claro Advisors position in Q1 2026.
  • Autolus Therapeutics made up ﹤0.01% of Claro Advisors's portfolio in Q1 2026, its #506 holding.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2026.

Based on Claro Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.